JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a $45 price target The firm continues to see a high level of enthusiasm for Edgewise’s multi-pronged strategy across neuromuscular and cardiovascular verticals driving the stock higher through 2025 and beyond. The firm cites its “high level of conviction” that the upcoming readout from the 28-day portion of the Phase 2 CIRRUS-HCM study for EDG-7500 in hypertrophic cardiomyopathy should be positive for the catalyst watch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- dgewise Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
- Edgewise Therapeutics Promotes Derakhshan to COO Role
- Edgewise Therapeutics promotes Behrad Derakhshan to COO
- Edgewise Therapeutics initiated with a Hold at Stifel
- Edgewise Therapeutics price target raised to $50 from $45 at Evercore ISI
Questions or Comments about the article? Write to editor@tipranks.com